Engineered extracellular vesicle capable of efficiently delivering circular RNA based on intracellular cyclization technology as well as construction method and application of engineered extracellular vesicle
By optimizing the circRNA expression vector and engineered EV membrane, the problem of low loading efficiency of circRNA in EVs was solved, enabling efficient delivery and tumor therapy applications, and demonstrating significant immune activation and anti-tumor functions.
Patent Information
- Application Number
- CN202610074311.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-01-20
- Publication Date
- 2026-04-14
AI Technical Summary
In existing technologies, extracellular vesicle (EV)-mediated circular RNA (circRNA) delivery suffers from low cargo loading efficiency, which limits its development in functional studies and therapeutic applications. In particular, traditional exogenous loading strategies damage vesicle integrity and the passive enrichment efficiency of circRNA in EVs is limited.
By designing circRNA expression vectors and optimizing their sequences, and combining them with RNA-binding proteins to engineer EV membranes, key regulatory genes are co-expressed, enhancing EV biogenesis and secretion, and establishing an efficient circRNA encapsulation and delivery platform.
This study achieved high-yield encapsulation and functional delivery of circRNA in extracellular vesicles, improved the transcription and translation efficiency of circRNA, enhanced the antigen presentation and activation functions of immune cells, and demonstrated significant anti-tumor effects.
Smart Images

Figure CN121852330A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of genetic engineering, and in particular to an engineered extracellular vesicle for efficient delivery of circular RNA based on intracellular circularization technology, its construction method, and its application. Background Technology
[0002] Extracellular vesicles (EVs) are nanoscale, membrane-coated particles secreted by cells into the extracellular environment and are key mediators of intercellular communication. EVs possess a favorable safety profile due to their natural origin, inherent biocompatibility, and ability to evade rapid clearance by macrophages and the reticuloendothelial system, resulting in low immunogenicity and cytotoxicity. Importantly, EVs exhibit superior cellular uptake efficiency compared to lipid nanoparticles (LNPs). This advantage stems from their inherent nanoscale size and the presence of natural membrane proteins, such as tetraspan proteins and integrins, which facilitate cellular recognition and internalization, making EVs a promising nucleic acid delivery platform. However, the clinical potential of EV-mediated RNA-encoding delivery (including messenger RNA (mRNA), microRNA (miRNA), and circular RNA (circRNA)) remains limited by low cargo loading efficiency, hindering their functional studies and therapeutic applications.
[0003] While traditional mRNA therapies are limited by the short half-life of linear transcripts in the cytoplasm, circRNA offers a compelling alternative. Its covalently closed structure confers stronger nuclease resistance, enabling more sustained protein expression in vivo. Therefore, therapeutic circRNAs can serve as a viable alternative to linear mRNAs for sustained protein expression. Lacking a 5' cap, circRNAs initiate translation via the internal ribosome entry site (IRES). Furthermore, efficient large-scale in vitro synthesis of circRNAs can be achieved through enzymatic circularization using T4 RNA ligase or through precise 3'-5' end ligation mediated by self-splicing introns (such as group I introns). However, loading synthesized circRNAs into vesicles (EVs) using exogenous strategies such as electroporation or sonication often compromises vesicle integrity and results in poor encapsulation. In contrast, endogenous loading strategies utilize cellular transcription and sorting mechanisms, enabling the encapsulation of larger and more complex biomolecules while maintaining EV membrane stability. However, a key challenge is the low intrinsic expression level of circRNAs in existing expression vectors, with transcript levels driven by endogenous processing elements (such as Alu or tRNA-mediated splicing) significantly lower than those of linear mRNAs. Furthermore, even with enhanced transcription, the efficiency of passive enrichment of circRNAs into EVs remains limited, necessitating the development of novel engineering methods to improve loading efficiency. Summary of the Invention
[0004] The purpose of this invention is to overcome the shortcomings and deficiencies of the prior art and provide an engineered extracellular vesicle for efficient delivery of circular RNA based on intracellular circularization technology.
[0005] Another objective of this invention is to provide a method for constructing engineered extracellular vesicles that efficiently deliver circular RNA based on intracellular circularization technology.
[0006] Another object of the present invention is to provide the application of the above-mentioned engineered extracellular vesicles for efficient delivery of circular RNA based on intracellular circularization technology.
[0007] The objective of this invention is achieved through the following technical solution: An engineered extracellular vesicle for efficient delivery of circular RNA based on intracellular circularization technology was constructed using the following method: (1) Synthesize a circular RNA expression fragment, insert it into a vector, and obtain a circular RNA expression vector; (2) Co-transfect the circular RNA expression vector and the delivery system expression vector into the cells; (3) After transfecting, the cells were cultured, the supernatant was centrifuged, filtered, and ultracentrifuged to obtain engineered extracellular vesicles that efficiently deliver circular RNA.
[0008] The circular RNA expression fragment described in step (1) is obtained by sequentially connecting fragment 1, spacer, fragment 2, IRES, target gene, and fragment 3.
[0009] The nucleotide sequence of fragment one is shown in SEQ ID NO.23.
[0010] The spacer is composed of random nucleotides of length 186 to 3186 bp; preferably, it is composed of random nucleotide sequences of any length of 186, 686, 1186, 1839, or 3186 bp; more preferably, it is composed of any nucleotide sequence shown in SEQ ID NO. 2 to 6.
[0011] The nucleotide sequence of fragment two is shown in SEQ ID NO.24.
[0012] The IRES is at least one of HCV, EV71, ECMV, CVB3 or HRVB3, and its nucleotide sequence is shown in SEQ ID NO.7-11.
[0013] The target gene is the gene that needs to be delivered for expression; preferably, it is at least one of GFP, Nluc, and OVA.
[0014] The nucleotide sequence of the target gene GFP is shown in SEQ ID NO.12.
[0015] The nucleotide sequence of the target gene Nluc is shown in SEQ ID NO.13.
[0016] The nucleotide sequence of the target gene OVA is shown in SEQ ID NO.14.
[0017] The nucleotide sequence of fragment three is shown in SEQ ID NO.25.
[0018] The nucleotide sequence of the circular RNA expression fragment described in step (1) is shown in SEQ ID NO.1.
[0019] The insertion in step (1) is between the endonuclease HindIII and XbaI.
[0020] The carrier mentioned in step (1) is pCDH.
[0021] The delivery system expression vectors described in step (2) include vectors capable of expressing CD63-Snu13, Exosome prodution enhancer, and DCpep-LAMP2B.
[0022] The nucleotide sequence of CD63-Snu13 is shown in SEQ ID NO.19.
[0023] The nucleotide sequence of the Exosome prodution enhancer is shown in SEQ ID NO.20.
[0024] The nucleotide sequence of DCpep-LAMP2B is shown in SEQ ID NO.21.
[0025] The vector is pcDNA3.
[0026] The delivery system expression vector is composed of CD63-Snu13, Exosome prodution enhancer, and DCpep-LAMP2B, which are respectively inserted between the restriction endonucleases BamHⅠ and XbaⅠ of the pcDNA3.1 vector.
[0027] The transfection described in step (2) is performed using PEI transfection reagent.
[0028] The cells mentioned in step (2) are HEK-293T cells.
[0029] The culture described in step (3) is carried out in a cell culture incubator at 37°C with 5% CO2.
[0030] The incubation time described in step (3) is 24 to 72 hours.
[0031] The centrifugation conditions described in step (3) are: centrifugation at 300×g for 10 minutes at 4°C, followed by centrifugation at 2000×g for 30 minutes, and then centrifugation at 10,000×g for 60 minutes.
[0032] The filtration in step (3) is filtration through a 0.22μm filter membrane.
[0033] The conditions for ultracentrifugation in step (3) are: 4°C, 200,000 × g for 120 minutes.
[0034] The above-mentioned engineered extracellular vesicles based on intracellular circularization technology for efficient delivery of circular RNA are used in the preparation of tumor vaccines.
[0035] The above-mentioned engineered extracellular vesicles based on intracellular circularization technology for efficient delivery of circular RNA are used in the preparation of tumor therapeutic drugs.
[0036] The above-mentioned engineered extracellular vesicles, which efficiently deliver circular RNA based on intracellular circularization technology, are used in the preparation of immune enhancers.
[0037] A tumor vaccine comprising the aforementioned engineered extracellular vesicles for efficient delivery of circular RNA based on intracellular circularization technology.
[0038] A tumor treatment drug comprising the aforementioned engineered extracellular vesicles for efficient delivery of circular RNA based on intracellular circularization technology.
[0039] The tumor in question is melanoma.
[0040] The present invention has the following advantages and effects compared with the prior art: This invention provides an engineered extracellular vesicle (EV) for efficient delivery of circular RNA based on intracellular circularization technology, along with its construction method and applications. To achieve efficient EV-mediated circRNA delivery, firstly, we designed a circRNA expression vector based on a tRNA splicing-mediated circularization mechanism and systematically optimized its sequence to improve transcription and translation efficiency in mammalian cells. Secondly, we engineered the EV membrane by demonstrating an RNA-binding protein capable of recognizing and enriching circRNA. Thirdly, we enhanced EV biogenesis and secretion by co-expressing key regulatory genes. By integrating these methods, we established a robust platform for high-yield encapsulation and functional delivery of circRNA, which has been validated in vivo. In summary, this work provides a scalable and efficient engineered framework for EV-based circRNA therapy, opening new avenues for RNA delivery. Attached Figure Description
[0041] Figure 1 It is the expression efficiency of inserting different spacer sequences into the CircRNA expression vector; Figure 2 It refers to the translation efficiency of inserting different IRES into a circRNA expression vector; Figure 3 It is the circularization efficiency of the CircRNA expression vector; Figure 4 It refers to the transfection efficiency of engineered exosomes delivering circRNA; Figure 5 It refers to the uptake and antigen presentation efficiency of engineered circRNA exosomes in immune cells; Figure 6 It refers to the antigen presentation and activation function of engineered circRNA exosomes in immune cells; Figure 7 It is the anti-tumor function of engineered circRNA exosomes; Figure 8 This is the function of engineered circRNA exosomes in inducing an immune response; Figure 9 It is pCDH-circRNA GFP Plasmid map of the -1839sp-HRVB3 vector. Detailed Implementation
[0042] The present invention will be further described in detail below with reference to the embodiments and accompanying drawings, but the embodiments of the present invention are not limited thereto.
[0043] Unless otherwise specified in the following implementation plan, the test conditions are generally as per standard test conditions or the test conditions recommended by the reagent company. Unless otherwise specified, all materials and reagents used are commercially available.
[0044] Example 1: Construction of an intracellular expression vector for circRNA The DNA fragment was synthesized by Qingke Biotechnology Co., Ltd., and the gene was then cloned into the pCDH expression vector. A synthetic sequence was inserted between the restriction endonucleases HindIII and XbaI to construct a circular RNA expression plasmid. This sequence contains a 5' UTR, IRES, Kozak sequence, coding region (CDS), C / D Box motif, and 3' UTR, flanked by Twister ribozyme sequences. Subsequently, spacer sequences of different lengths were introduced between the CMV promoter and the Twister ribozyme sequences. The C / D Box motif can bind to the RNA-binding protein Snu13.
[0045] The sequence structure of the circRNA expression vector is as follows: CMV Promoter, Spacer, Twister Ribozyme 5', Ligation Area 5', 5' UTR, IRES, GFP, C / D Box, 3' UTR, Ligation Area 3', Twister Ribozyme 3'.
[0046] Example 2: Expression and Characterization of the Vector 2.1 Expression of the Carrier 2 μg of the circRNA expression vector plasmid containing GFP protein with different length spacer sequences prepared in Example 1 was mixed with 4 μL of jetprime transfection reagent in the transfection buffer. After vortexing the mixture, it was allowed to stand for 5 minutes. The mixture was then added to HEK-293T cells for incubation. The cells were cultured at 37°C in a cell culture incubator containing 5% CO2.
[0047] 2.2 Optimization of spacer sequences To improve the transcription and translation efficiency of circRNA expression vectors, the length of the spacer sequence in the vector was adjusted. Following the method in Example 1, HCV was used as the IRES, and spacer sequences (nucleotide sequences as shown in SEQ ID NO. 2-6) with lengths of 186, 686, 1186, 1839, and 3186 bp were selected to construct vectors, resulting in five vectors containing spacer sequences of different lengths for subsequent expression and characterization.
[0048] 2.3 Characterization of Expressive Effect After 48 hours of culture, the treated cells were imaged using an inverted fluorescence microscope. GFP expression efficiency was analyzed by flow cytometry.
[0049] Experimental results are as follows Figure 1 As shown, the vector containing the 1839 bp spacer sequence exhibited the highest GFP expression level after transformation into cells. Subsequent use of this pCDH-circRNA... GFP Experiments were conducted using the -1839sp vector.
[0050] Example 3: Effects of different IRES on the translation efficiency of circRNA expression vectors To further improve the translation efficiency of the circRNA expression vector, the pCDH-circRNA constructed in Example 2 was used. GFPBased on the -1839sp vector, vectors containing different IRES were prepared by replacing the IRES of the inserted sequence with HCV, EV71, ECMV, CVB3 or HRVB3 (nucleotide sequences as shown in SEQ ID NO. 7-11). Then, the vectors were expressed and characterized according to the method in Example 2 to verify the expression effect.
[0051] Experimental results are as follows Figure 2 As shown, the expression level of GFP was highest after the vector containing HRVB3 was transfected into cells. Subsequent use of pCDH-circRNA... GFP Experiments were conducted using the -1839sp-HRVB3 carrier.
[0052] Example 4: Determination of circularization efficiency of circRNA expression vector pCDH-circRNA was expressed according to the method in 2.1 of Example 2. GFP Cells were collected after incubating the -1839sp-HRVB3 vector for 48 hours. RNA was extracted from the cells using Freezol reagent (Novitamin) according to the manufacturer's instructions, and the RNA concentration was measured. 1 μg of RNA was reverse transcribed using the HiScript III 1st Strand cDNA Synthesis Kit (Yisheng). qPCR was then performed using the Hieff qPCR SYBR Green Master Mix kit (Yisheng) according to the manufacturer's instructions. A standard curve was plotted, and the copies of the opposing and reverse primers for the circRNA expression vector were calculated to determine the circularization efficiency. The primer sequences used are as follows: GFP-qPCR-F (opposite primers): CGTGACCACCCTGACCT; GFP-qPCR-R (opposite primers): CACCTTGATGCCGTTCTT; TornadoOpti-CJ-F (backward primer): CCCCGTGGTCTTTGA; TornadoOpti-CJ-R (backward primer): GTTGGTTGGCGGATAA.
[0053] Experimental results are as follows Figure 3 As shown, the efficiency of circRNA expression vectors in generating circRNA in cells is approximately 60%.
[0054] Example 5 Construction of an engineered exosome-loaded circRNA system 5.1 Construction and transfection of delivery system-related vectors To establish an efficient extracellular vesicle (EV) platform for circRNA delivery, we employed a dual-strategy approach aimed at simultaneously improving circRNA encapsulation efficiency and EV yield. The first strategy involved engineering the EV membrane to exhibit RNA-binding proteins capable of selectively enriching circRNA. The second strategy focused on enhancing intracellular EV biosynthesis and secretion pathways to increase total EV yield, thereby increasing the absolute circRNA load. Furthermore, to enhance circRNA targeting, targeting peptides were modified onto the exosome membrane to target antigen-presenting cells. To achieve this, the Snu13 protein was fused to the C-terminus of the CD63 protein, which binds to the C / D Box motif on circRNA, thereby enriching it in exosomes. Subsequently, co-transfection with exosome secretion-promoting proteins further increased exosome yield.
[0055] The genes used in this embodiment were cloned into the pcDNA3.1 vector, including CD63-Snu13, Exosome production enhancer, and DCpep-LAMP2B (nucleotide sequences shown in SEQ ID NO. 12-14). After gene synthesis, the above DNA was inserted between the restriction endonucleases BamH Ⅰ and XbaⅠ in the pcDNA3.1 vector to construct pcDNA3-CD63-Snu13, pcDNA3-Exosome production enhancer, and pcDNA3-DCpep-LAMP2B.
[0056] HEK-293T cells were seeded in 6-well plates according to... Figure 4 Different experimental groups in setting A used 10 μL of PEI transfection reagent with 2000 ng pCDH-circRNA. Nluc -1839sp-HRVB3 (pCDH-circRNA) GFP The GFP gene in -1839sp-HRVB3 was replaced with the Nluc gene, the nucleotide sequence of which is shown in SEQ ID NO.13. The plasmids were co-transfected with one or more of the following plasmids: 1000 ng pcDNA3-CD63-Snu13, 500 ng pcDNA3-Exosome prodution enhancer, and 500 ng pcDNA3-DCpep-LAMP2B.
[0057] 5.2 Extraction and Effect Verification of EV Forty-eight hours after transfection and culture medium replacement, the culture supernatant was harvested from the producing cells. After centrifugation to remove cell debris, the clarified supernatant was applied to recipient cells in 24-well plates at 60-80% confluence. For large-scale purification and isolation of EVs, differential centrifugation was used. Specifically, the supernatant underwent a series of centrifugation steps: first, centrifugation at 300×g for 10 min, followed by centrifugation at 2000×g for 30 min, and then centrifugation at 10,000×g for 60 min, all performed at 4°C to remove cells and cell debris. Subsequently, the clarified supernatant was filtered through a 0.22 μm filter membrane (Millipore, USA). The filtrate was ultracentrifuged at 200,000×g for 120 min at 4°C using an Optima MAX-XP ultracentrifuge (Beckman Coulter, USA). The final exosome (EV) pellet was resuspended in phosphate-buffered saline (PBS) for subsequent use.
[0058] After 24 hours of incubation, the activity of nanoluciferase in recipient cells was assessed using a nanoluciferase reporter gene assay kit (Bolotech Biotechnology). Briefly, 200 µL of cell suspension was mixed with 200 µL of a quantitative reagent prepared by diluting 4 µL of nanoluciferase assay substrate in 200 µL of nanoluciferase assay buffer. The mixture was homogenized by pipetting, and 100 µL of the resulting solution was transferred to a white 96-well plate. Luminescence was measured at 25 °C using a Tecumseh Infinite E Plex system with an integration time of 1 second per well. Results are expressed in relative light units (RLU).
[0059] Experimental results are as follows Figure 4 As shown, the combination of four plasmids simultaneously achieved the highest transfection efficiency in 293T cells. Figure 4 (A), and then the exosomes were transfected into primary BMDC cells, and it was found that the engineered exosomes could successfully transfect BMDC cells ( Figure 4 (B)
[0060] Example 6: Uptake and antigen presentation of engineered circRNA exosomes by immune cells 6.1 Isolation and preparation of mouse BMDC cells Female C57BL / 6 mice were euthanized and disinfected with 70% ethanol. Femurs and tibias were dissected to collect bone marrow cells. After lysing red blood cells with erythrocyte lysis buffer, the remaining cells were resuspended in RPMI-1640 complete medium supplemented with 20 ng / mL granulocyte-macrophage colony-stimulating factor (GM-CSF). On day 3, an equal volume of fresh medium containing 20 ng / mL GM-CSF was added. On day 6, half of the medium was replaced with fresh medium containing GM-CSF. BMDCs were harvested between days 7 and 9 and seeded onto plates for subsequent experiments.
[0061] 6.2 Cell uptake rate determination To assess cellular uptake, fluorescently labeled circRNAs were performed using the Beyotime PKH-67 Green Fluorescent Cell Kit, following the manufacturer's instructions. ova -DCpep@EVs (pCDH-circRNA) GFP The EVs obtained by transfecting cells with the OVA gene after replacing the GFP gene in -1839sp-HRVB3 were cultured and extracted. The specific method can be found in the aforementioned examples. The nucleotide sequence of OVA is shown in SEQ ID NO.17, and the nucleotide sequence of the entire inserted synthetic sequence is shown in SEQ ID NO.1. EVs containing 1×10 9 PKH67-labeled EV particles were resuspended and co-incubated with BMDCs seeded in 24-well plates at 37°C for 0, 2, 4, and 8 hours. After incubation, cells were washed with PBS and fixed with 4% paraformaldehyde. Nuclei were counterstained with DAPI, and EV uptake was observed using confocal microscopy.
[0062] 6.3 Antigen Presentation Analysis To perform antigen presentation analysis, BMDCs were seeded in 24-well plates and treated with 5 × 10⁻⁶ ppm. 9 Any treatment of circRNA particles ova @EVs or circRNA ova -DCpep@EVs. At time points of 0, 6, 12, 24, 36, and 48 hours post-treatment, the expression of the MHC I-OVA complex was analyzed by flow cytometry using the T-Select H-2Kb OVA tetramer SIINFEKL APC antibody (BetterGen). Successful antigen processing and presentation were assessed by monitoring the surface display of the MHC I-OVA complex.
[0063] 6.4 Experimental Results Cell uptake results are as follows Figure 5 As shown in Figure A, BMDCs affect circRNAova -DCpep@EVs uptake reaches peak efficiency at 8 hours.
[0064] Antigen presentation analysis such as Figure 5 As shown in Figure B, the expression level of MHC I-OVA peaked 6 hours after treatment. Notably, within 48 hours, circRNA expression... ova -DCpep@EVs formulations exhibited significantly longer sustained antigen presentation time than the non-targeted control (circRNA). ova @EVs).
[0065] Example 7: Function of engineered circRNA exosomes in activating immune cells 7.1 Laboratory Animals Six- to eight-week-old C57BL / 6 mice (Guangzhou Tengke Biomedical Co., Ltd.) were randomly divided into four groups, and the mice were subcutaneously injected with 100 μL PBS, 1×10⁻⁶ PBS, and 1×10⁻⁶ PBS, respectively. 11 1 × 10 293T cells EVs (obtained from untransfected 293T cells according to method 5.2 in Example 5), 1 × 10 11 circRNA ova @EVs (prepared according to the method in Example 5, except that the pcDNA3-DCpep-LAMP2B plasmid was not added when constructing the delivery system) and 1×10 11 circRNA ova -DCpep@EVs was used to assess the activation status of dendritic cells.
[0066] 7.2 Experimental Procedure To assess antigen presentation and dendritic cell activation, inguinal lymph nodes were collected 24 hours post-injection. Specifically, mice were sacrificed 24 hours post-injection, and bilateral inguinal lymph nodes were aseptically harvested. The lymph nodes were placed in pre-chilled PBS. In a culture dish, the lymph nodes were gently mechanically abraded using the flat end of a 1 mL syringe plunger to pass through a 70 μm cell sieve. The sieve was rinsed with an appropriate amount of buffer to collect all cells. The obtained cell suspension was transferred to centrifuge tubes and centrifuged at 300–400 × g for 5 minutes (4°C), then the supernatant was discarded. The cell pellet was resuspended in an appropriate amount of pre-chilled PBS, and cell counting and viability assays (e.g., trypan blue staining) were performed.
[0067] Take 1×10 6Lymph node cells were stained using the following fluorescently conjugated antibodies according to standard staining protocols: FITC anti-mouse CD11c, PE-Cy7 anti-mouse CD86, BV421 anti-mouse CD40, and H-2Kb OVA tetramer SIINFEKL APC. The cells and antibody mixture were incubated at 4°C in the dark for 20–30 minutes. After incubation, the cells were washed with 2–3 mL of staining buffer (PBS containing 1% FBS), centrifuged at 300–400 × g for 5 minutes (4°C), and the supernatant was discarded. This process was repeated once. The stained cells were resuspended in an appropriate amount of staining buffer and immediately subjected to flow cytometry analysis to assess cell population and activation status.
[0068] 7.3 Experimental Results Experimental results are as follows Figure 6 As shown, compared with the control group, all EV-based vaccines significantly enhanced the maturation of BMDCs, as indicated by the upregulation of the surface expression of co-stimulatory molecules CD40 and CD86. Figure 6 (A and B). Furthermore, EV-based vaccines also significantly enhanced antigen presentation levels in BMDC cells ( Figure 6 (C and D). Notably, the exosome membrane surface modification DCpep has a stronger effect on the activation and antigen presentation of BMDC cells.
[0069] Example 8: Immune response and antitumor effects of engineered circRNA exosome vaccine in mice. 8.1 Laboratory Animals and Modeling C57BL / 6 mice were subcutaneously injected with 5 × 10 5 Five mice were inoculated with B16-OVA melanoma cells. Five days after inoculation, mice that successfully modeled melanoma were randomly assigned to different experimental groups, with five mice in each group and three replicates for each experimental group.
[0070] 8.2 Experimental Procedure Mice were treated with the following medication three times, once every four days: 100 μL PBS, 1 × 10 11 293 T cells EV, 1×10 11 circRNA ova @EVs, or 1×10 11 circRNA ova -DCpep@EVs. Mice exhibiting severe morbidity were euthanized prior to the endpoint.
[0071] All remaining mice were sacrificed on day 20 post-tumor inoculation, and spleens were harvested for further analysis. The spleens were milled and passed through a 70 μm cell filter to obtain a single-cell suspension. Splenic lymphocytes were isolated using mouse lymphocyte separation solution (Dake Biotech). Red blood cells were lysed by incubation at 4°C with red blood cell lysis buffer (White Shark Biotech) for 5 minutes, followed by washing with RPMI 1640 medium. The purified lymphocytes were resuspended in RPMI 1640 medium supplemented with 10% FBS, 2 mM glutamine, and 1% penicillin / streptomycin for subsequent analysis.
[0072] IFN-γ ELISpot assays were performed using a mouse IFN-γ pre-coated ELISpot kit (Dakow Biotech). Briefly, 96-well ELISpot plates were washed with PBS and coated overnight at 4°C with purified rat anti-mouse IFN-γ monoclonal antibody. 100 μL of a solution containing 5 × 10⁻⁶ IFN-γ was added to each well. 5 Mouse spleen cells. Then, OVA at a concentration of 4 mg / mL was used. 257-264 Cells were stimulated with peptide (MCE). Dimethyl sulfoxide (DMSO) and 500 ng / mL PMA + 10 μg / mL iomycin were used as negative and positive controls, respectively. After 24 hours of incubation, plates were incubated with biotinylated detection antibodies, followed by imaging with alkaline phosphatase-conjugated streptavidin and NBT / BCIP substrate.
[0073] 8.3 Experimental Results Experimental results are as follows Figures 7-8 As shown, where Figure 7 Tumor growth kinetics and analysis showed that circRNA ova @EVs and circRNA ova Compared with the PBS and natural EV control groups, the DCpep@EV vaccine group showed significant inhibition of tumor progression. Furthermore, the DCpep-modified vaccine group on the exosome membrane induced more antigen-specific T lymphocytes, exhibiting stronger anti-tumor function. Figure 8 ).
[0074] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.
Claims
1. An engineered extracellular vesicle for efficient delivery of circular RNA based on intracellular circularization technology, characterized in that... It is constructed using the following method: (1) Synthesize a circular RNA expression fragment, insert it into a vector, and obtain a circular RNA expression vector; (2) Co-transfect the circular RNA expression vector and the delivery system expression vector into the cells; (3) After transfecting, the cells were cultured, the supernatant was centrifuged, filtered, and ultracentrifuged to obtain engineered extracellular vesicles that efficiently deliver circular RNA.
2. The engineered extracellular vesicles for efficient delivery of circular RNA based on intracellular circularization technology according to claim 1, characterized in that: The circular RNA expression fragment described in step (1) is obtained by sequentially connecting fragment 1, spacer, fragment 2, IRES, target gene, and fragment 3. The nucleotide sequence of fragment one is shown in SEQ ID NO.23; The spacer is composed of random nucleotides with a length of 186–3186 bp; The nucleotide sequence of fragment two is shown in SEQ ID NO.24; The IRES is at least one of HCV, EV71, ECMV, CVB3 or HRVB3, and its nucleotide sequence is shown in SEQ ID NO. 7 to 11. The target gene is the target gene that needs to be delivered for expression. The nucleotide sequence of fragment three is shown in SEQ ID NO.25; The carrier mentioned in step (1) is pCDH; The insertion in step (1) is between the endonuclease HindIII and XbaI.
3. The engineered extracellular vesicles for efficient delivery of circular RNA based on intracellular circularization technology according to claim 2, characterized in that: The target gene is at least one of GFP, Nluc, and OVA; The nucleotide sequence of the target gene GFP is shown in SEQ ID NO.12; The nucleotide sequence of the target gene Nluc is shown in SEQ ID NO.13; The nucleotide sequence of the target gene OVA is shown in SEQ ID NO.
14.
4. The engineered extracellular vesicles for efficient delivery of circular RNA based on intracellular circularization technology according to claim 1, characterized in that: The nucleotide sequence of the circular RNA expression fragment described in step (1) is shown in SEQ ID NO.
1.
5. The engineered extracellular vesicles for efficient delivery of circular RNA based on intracellular circularization technology according to claim 1, characterized in that: The delivery system expression vectors described in step (2) include vectors capable of expressing CD63-Snu13, Exosome prodution enhancer, and DCpep-LAMP2B; The nucleotide sequence of CD63-Snu13 is shown in SEQ ID NO.19; The nucleotide sequence of the Exosome product enhancer is shown in SEQ ID NO.20; The nucleotide sequence of DCpep-LAMP2B is shown in SEQ ID NO.21; The vector is pcDNA3.
6. The engineered extracellular vesicles for efficient delivery of circular RNA based on intracellular circularization technology according to claim 1, characterized in that: The transfection described in step (2) is performed using PEI transfection reagent; The cells mentioned in step (2) are HEK-293T cells.
7. The engineered extracellular vesicles for efficient delivery of circular RNA based on intracellular circularization technology according to claim 1, characterized in that: The culture described in step (3) is carried out in a cell culture incubator at 37°C with 5% CO2. The incubation time described in step (3) is 24 to 72 hours.
8. The application of engineered extracellular vesicles based on intracellular circularization technology for efficient delivery of circular RNA as described in any one of claims 1 to 7 in the preparation of tumor vaccines.
9. The application of engineered extracellular vesicles based on intracellular circularization technology for efficient delivery of circular RNA as described in any one of claims 1 to 7 in the preparation of tumor therapeutic drugs.
10. A tumor treatment drug comprising engineered extracellular vesicles for efficient delivery of circular RNA based on intracellular circularization technology as described in any one of claims 1 to 7.
